Positive data for Amgen’s olpasiran could accelerate Phase III

Amgen’s cardiometabolic R&D focus has taken a step forward with data from a Phase II study of olpasiran suggesting the siRNA therapy reduces Lp(a) levels as hoped.

On Tuesday, the company reported that olpasiran, dosed at up to 225 mg subcutaneously every 12 weeks, reduced levels of its lipoprotein(a) target by “up to or greater than” 90% across the majority of doses at week 36 — the primary endpoint — and week 48. The full dataset from the 281-patient study will be presented at an upcoming meeting...